A Phase I Open-Label Trial to Investigate the Effect of Severe Renal Impairment on the Single-Dose Pharmacokinetics of Telaprevir.

Trial Profile

A Phase I Open-Label Trial to Investigate the Effect of Severe Renal Impairment on the Single-Dose Pharmacokinetics of Telaprevir.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Mar 2010

At a glance

  • Drugs Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 26 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Planned end date changed from 1 Jan 2010 to 1 Feb 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top